TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9203723

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) at 4 and 9 months of age
Number of subjects: 16566
Study: 8291408

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg 3 times daily for 2 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3561773

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30929011

Group type: EXPERIMENTAL
Intervention: % inorganic arsenic in urine
Number of subjects: 12609

Group type: EXPERIMENTAL
Intervention: % monomethylarsenate in urine
Number of subjects: 12609

Group type: EXPERIMENTAL
Intervention: % dimethylarsinate in urine
Number of subjects: 12609
Study: 29274643

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard practice (Control)
Number of subjects: 90
Study: 26253175

Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 68
Study: 24839241

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5mg yearly infusion
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1486
Study: 22153327

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO‐OP) intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Contemporary treatment or task-specific training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dynamic Performance Analysis (DPA)
Number of subjects: 13
Study: 20505273

Group type: EXPERIMENTAL
Intervention: Bilateral or recurrent lesions of ocular adnexal lymphoma
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral orbital lesions, rectum, and stomach lesions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Original and recurrent conjunctival lesions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral orbital or conjunctival lesions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orbital lesion and oral cavity lesion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral orbital lesions, buccal, rectum, and stomach lesions
Number of subjects: 10
Study: 17490954

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) at a dose of 3.2 g/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 18
Study: 16308498

Group type: EXPERIMENTAL
Intervention: BC-guided PV isolation
Number of subjects: 100

Group type: COMPARATOR
Intervention: CC-guided PV isolation
Number of subjects: 100
Study: 12184034

Group type: EXPERIMENTAL
Intervention: Antimalarial therapy
Number of subjects: 0
Study: 9805696

Group type: EXPERIMENTAL
Intervention: Traditional approach (blind placement through the larynx)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Directed approach (intubation under direct vision using fiberoptic bronchoscope)
Number of subjects: 58
Study: 7615916

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress management interventions (general)
Number of subjects: 0
Study: 2792753

Group type: EXPERIMENTAL
Intervention: Peanut food challenge
Number of subjects: 71
Study: 770226

Group type: EXPERIMENTAL
Intervention: 15 (R)‐15‐methyl PGE2 methyl ester
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 15 (S)‐15‐methyl PGE2 methyl ester
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 16, 16‐dimethyl PGE2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31394600

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 71
Study: 27541997

Group type: EXPERIMENTAL
Intervention: Total atrial conduction time (TACT) measured by PA‐TDI interval via echocardiography
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc score
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Longer PA‐TDI interval
Number of subjects: 90
Study: 25361685

Group type: EXPERIMENTAL
Intervention: Self-reported medication non-adherence
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Life chaos score
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Worry about stroke
Number of subjects: 405
Study: 23183356

Group type: EXPERIMENTAL
Intervention: Tyrothricin 0.1% gel
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vehicle gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated test fields
Number of subjects: 33
Study: 21450978

Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted H1N1 vaccine containing 3.75 μg hemagglutinin (HA)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1 vaccine containing 15 μg HA
Number of subjects: 261

Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1 vaccine containing 3.75 μg HA
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: AS03(A) adjuvant
Number of subjects: 261
Study: 18649012

Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (5 x 10(9) pfu)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (1 x 10(10) pfu)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer (2 x 10(10) pfu)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ad-hHGF gene transfer
Number of subjects: 18
Study: 17892986

Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (EPO) for 4 months followed by maintenance for another 8 months, with oral iron throughout 12 months.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group received saline as placebo and oral iron throughout 12 months.
Number of subjects: 51
Study: 15471829

Group type: EXPERIMENTAL
Intervention: Delayed 18F‐FDG PET imaging
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Extended-time data analysis
Number of subjects: 19
Study: 11561827

Group type: EXPERIMENTAL
Intervention: 600 microg of intravaginal misoprostol every 12 hours
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 800 microg of intravaginal misoprostol every 12 hours
Number of subjects: 143
Study: 9773717

Group type: EXPERIMENTAL
Intervention: Implantable Insulin Pump (IIP) therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Multiple-Dose Insulin (MDI) therapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 121
Study: 8148225

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with norfloxacin (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with ciprofloxacin (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (100 mg elemental iron) with ofloxacin (400 mg)
Number of subjects: 8
Study: 3167505

Group type: EXPERIMENTAL
Intervention: Peritendonous injection of 40 mgs of methyl prednisolone acetate (Depo Medrone)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2 ml of 0.25% marcaine alone
Number of subjects: 28
Study: 4943606

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 31874736

Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy (GDFT) using non-invasive cardiac output monitoring for 12 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GDFT
Number of subjects: 60
Study: 30974240

Group type: EXPERIMENTAL
Intervention: Complex training (n=18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Simple training (n=17)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Passive control group (n=19)
Number of subjects: 54
Study: 29292264

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (single anesthetic agent)
Number of subjects: 124
Study: 25877225

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² for level 1 and 1200 mg/m² for level 2 on day 1), Cisplatin (30 mg/m² fixed dose on day 1), S-1 (40-60 mg/day fixed dose twice a day for 7 days), every 2 weeks until progression
Number of subjects: 18
Study: 23571166

Group type: EXPERIMENTAL
Intervention: One dose of AS03‐adjuvanted H1N1 2009 vaccine (3.75 µg Hemagglutinin antigen)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Two doses of AS03‐adjuvanted H1N1 2009 vaccine (3.75 µg Hemagglutinin antigen, 21 days apart)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Two doses of H1N1 2009 vaccine
Number of subjects: 240
Study: 21552482

Group type: EXPERIMENTAL
Intervention: Guided internet self-help treatment program (22 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 42
Study: 19940609

Group type: EXPERIMENTAL
Intervention: 40 mg/day laropiprant
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16728292

Group type: EXPERIMENTAL
Intervention: Tailored stage‐matched intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study: 15324780

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cold Pressor Test
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pressure pain tolerance
Number of subjects: 17
Study: 11513787

Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Double-gloving system
Number of subjects: 885

Group type: COMPARATOR
Intervention: Combination gloves
Number of subjects: 885
Study: 9096447

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy for 6 months in group I (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy and iron supplement in group II (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mathematical method for estimating iron needs
Number of subjects: 40
Study: 8502627

Group type: EXPERIMENTAL
Intervention: Single 800 mg dose of pefloxacin
Number of subjects: 482

Group type: COMPARATOR
Intervention: 10 days' course of norfloxacin 400 mg bid
Number of subjects: 482
Study: 3573825

Group type: EXPERIMENTAL
Intervention: Calcium infusion (2 mg/kg over 5 minutes)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 micrograms/kg as a bolus)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Basal plasma levels of calcitonin in normal men
Number of subjects: 159

Group type: COMPARATOR
Intervention: Basal plasma levels of calcitonin in normal women
Number of subjects: 159
Study: 28815430

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 27659276

Group type: EXPERIMENTAL
Intervention: 5% benzocaine gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 24100112

Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy (20 mg omeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 1 week)
Number of subjects: 901

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 901
Study: 22662132

Group type: EXPERIMENTAL
Intervention: Topical insulin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20137365

Group type: EXPERIMENTAL
Intervention: 30‐minute formula electro‐acupuncture treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 18441312

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 55 IU (68 USP) of ovine hyaluronidase (Vitrase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 75 IU (93 USP) of ovine hyaluronidase (Vitrase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 15583944

Group type: EXPERIMENTAL
Intervention: Potentiometric immunosensor for adrenal cortical hormones (ACH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ELISA method
Number of subjects: 0
Study: 12860806

Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 842

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 842
Study: 14655916

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (at least 225 minutes per week)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Increase in maximum O2 consumption (>10% increase)
Number of subjects: 173
Study: 9521952

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral suspension (10 mg/kg body weight, three times daily)
Number of subjects: 16
Study: 7570860

Group type: EXPERIMENTAL
Intervention: Preventive therapy for tuberculosis
Number of subjects: 475

Group type: COMPARATOR
Intervention: Reasons for not entering the trial
Number of subjects: 475
Study: 2575985

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 87

Group type: COMPARATOR
Intervention: both treatments
Number of subjects: 87
Study: 1001131

Group type: EXPERIMENTAL
Intervention: Dipyridamol/Acetylsalicylic Acid (ASA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASA) alone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31706099

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily until disease progression, death, or withdrawal
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 225
Study: 30776136

Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 51989

Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 51989
Study: 27871928

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 42
Study: 25769003

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin daily
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin daily
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Low dose atorvastatin
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Statin treated patients
Number of subjects: 1193
Study: 23826798

Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care for Preschoolers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 21605732

Group type: EXPERIMENTAL
Intervention: Decision aid (tailored pictographic 10-year fracture risk estimate, absolute risk reduction with bisphosphonates, side effects, and out-of-pocket cost)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (standard brochure)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 18538536

Group type: EXPERIMENTAL
Intervention: Quad sparing approach
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard median parapatellar incision
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mini mid-vastus approach
Number of subjects: 59
Study: 17083766

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and prednisolone
Number of subjects: 0
Study: 15305885

Group type: EXPERIMENTAL
Intervention: Intralipid with heparin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intralipid alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 9
Study: 10708327

Group type: EXPERIMENTAL
Intervention: Community-based drug prevention, education, and treatment projects providing case management and referral to services or day treatment
Number of subjects: 370

Group type: COMPARATOR
Intervention: Alternative or no intervention
Number of subjects: 370
Study: 9081694

Group type: EXPERIMENTAL
Intervention: Immediate dietary intervention (NCEP step II diet)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Delayed dietary intervention (control group)
Number of subjects: 409
Study: 8471129

Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31467033

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 215

Group type: COMPARATOR
Intervention: IFN β‐1a
Number of subjects: 215
Study: 29609644

Group type: EXPERIMENTAL
Intervention: Enhanced Psychological Care (EPC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 29
Study: 27500639

Group type: EXPERIMENTAL
Intervention: DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine
Number of subjects: 0
Study: 24377454

Group type: EXPERIMENTAL
Intervention: Pistachio nuts (20% energy daily)
Number of subjects: 60
Study: 22592096

Group type: EXPERIMENTAL
Intervention: 0.5-1.0 µg calcitriol and 1200 IU (30 µg) cholecalciferol
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Increases in 1,25-dihydroxyvitamin D
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Changes in parathyroid hormone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 61
Study: 20642344

Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group (N = 60)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group with annual household income < $50,000
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ocular sarcoidosis group with visual acuity 20/100 or worse
Number of subjects: 95

Group type: COMPARATOR
Intervention: Non-ocular sarcoidosis group (N = 35)
Number of subjects: 95
Study: 18678155

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Shuigou (GV 26) plus western medicine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 276
Study: 15779698

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat diets
Number of subjects: 0
Study: 12905485

Group type: EXPERIMENTAL
Intervention: Limited disease
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Severe disease
Number of subjects: 180
Study: 10367592

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (n = 11)
Number of subjects: 22
Study: 9087091

Group type: EXPERIMENTAL
Intervention: RSV immune globulin (RSV-IG)
Number of subjects: 0
Study: 1677361

Group type: EXPERIMENTAL
Intervention: Clonidine (0.300 mg, orally) and Pyridostigmine (120 mg, orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg, im)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg, im) and Clonidine (0.300 mg, orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Yohimbine (30 mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6342357

Group type: EXPERIMENTAL
Intervention: Coingestion of 50 g fat (butter) with 50 g carbohydrate (potato)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Coingestion of 50 g fat (butter) with 50 g protein (low fat veal)
Number of subjects: 8
Study: 31237182

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) after four treatments
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Severely depressed patients
Number of subjects: 69
Study: 29987144

Group type: EXPERIMENTAL
Intervention: 400 mg of Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 800 mg of Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 26872898

Group type: EXPERIMENTAL
Intervention: Gauze dressings soaked in normal saline at 42°C (experimental)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gauze dressings soaked in normal saline at room temperature (control)
Number of subjects: 10
Study: 24414439

Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 100
Study: 22365709

Group type: EXPERIMENTAL
Intervention: Definity (10 μL/kg) as a slow bolus over 30 to 60 sec
Number of subjects: 32
Study: 20202514

Group type: EXPERIMENTAL
Intervention: Olmesartan (10 to 40 mg)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 247
Study: 17210069

Group type: EXPERIMENTAL
Intervention: ATP infusions with usual palliative care and dietetic advice
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual palliative care and dietetic advice without ATP
Number of subjects: 100
Study: 15757771

Group type: EXPERIMENTAL
Intervention: Static splintage
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interphalangeal joint mobilization with metacarpophalangeal joint immobilization
Number of subjects: 42

Group type: COMPARATOR
Intervention: Norwich regime
Number of subjects: 42
Study: 11925464

Group type: EXPERIMENTAL
Intervention: Whole almonds (WA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Almond oil (AO)
Number of subjects: 22
Study: 9583926

Group type: EXPERIMENTAL
Intervention: Levodopa and a dopa decarboxylase inhibitor in combination with selegiline (arm 2)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Levodopa and a dopa carboxylase inhibitor (arm 1)
Number of subjects: 624
Study: 8563903

Group type: EXPERIMENTAL
Intervention: Semi-elemental diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-residue diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0
Study: 2696670

Group type: EXPERIMENTAL
Intervention: 10 mg intravitreal 5-FU
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no 5-FU)
Number of subjects: 51
Study: 797205

Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control
Number of subjects: 119